Dr. Audoly is a serial biotech entrepreneur and senior executive in the biotech/pharma industry. He has contributed to the identification and development of multiple novel drug approvals addressing unmet medical need across multiple disease areas, generating more than $2B in annual sales (Xeljanz®, Hemangiol®, Braftovi®, Renflexis®, Brenzys®, Ontruzant®, Hadlima®). He is co-founder of Cytovia Therapeutics, a cell therapy development stage biotech focused on targeting NK cells against tumors; and founder/CEO of Parthenon Therapeutics, a precision oncology biotech focused on breaking down the tumor’s barriers that prevent immune cells from infiltrating and eliminating tumors. He also serves as a board member and advisor to a number of biotech/pharma organizations. Prior to Parthenon, Dr. Audoly was at the helm of Kymera as its founding CEO (Nasdaq: KYMR). Earlier in his career, he held positions of increasing leadership responsibilities at Pfizer, Merck, and biotech companies as CSO and head of R&D, contributing to the advancement of 21 drug candidates into and through clinical development. Dr. Audoly has completed pharma/biotech transactions worth over $3B in biobucks and raised more than $250 million. He is an inventor and authored over 70 papers and patents. He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and completed postdoctoral training at UNC/Chapel Hill and Duke University where he was the recipient of an American Heart Association Fellowship.
Making progress and achieving milestones to create innovative medicines